B-Cell References

  1. Jaffe ES, Harris NL, Stein H, et al. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev 4th ed. Lyon, France: International Agency for Research on Cancer; 2017:190-198.
  2. Leukaemia Foundation. Diffuse large B-cell lymphoma (DLBCL). Leukaemia Foundation Website. http://www.leukaemia.org.au/blood-cancers/lymphomas/non-hodgkin-lymphoma-nhl/diffuse-large-b-cell-lymphoma. Accessed June 4, 2018.
  3. Noone AM, Howlader N, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2015. National Cancer Institute website. https://seer.cancer.gov/csr/1975_2015/browse_csr.php?sectionSEL=19&pageSEL=sect_19_table.29.html. Accessed June 4, 2018.
  4. Fameli-Pavlaki M. Diffuse large B-cell lymphoma–part I: towards homogeneity. Haema. 2005;8:201-214.
  5. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011:498-505. PMID: 22160081
  6. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417-1429. PMID: 20393178
  7. Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Program. 2013:584-590. PMID: 24319235
  8. Narayanan S, Savage KJ. Staging and prognostic factors. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:149-171.
  9. Armitage JO, Mauch PM, Harris NL, Dalla-Favera R, Bierman PJ. Diffuse large B-cell lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:304-326.
  10. Manson SD, Porter C. Lymphomas. In: Yarbro CH, Frogge MH, Goodman M, eds. Cancer Nursing: Principles and Practice. 6th ed. Sudbury, MA: Jones & Bartlett Publishers; 2005:1414-1459.
  11. Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med. 2008;132:565-578. PMID: 18384208
  12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.4.2018. © National Comprehensive Cancer Network, Inc 2018. All rights reserved. Published May 15, 2018. Accessed June 4, 2018. To view the most recent and complete version of the guidelines go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  13. Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med. 2008;132:118-124. PMID: 18181663
  14. Good DJ, Gascoyne RD. Diagnosis: diagnostic procedures, histopathologic problems, immunophenotyping, and applied genetics. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:132-148.
  15. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068. PMID: 25113753
  16. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994. PMID: 8141877
  17. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323. PMID: 19038878
  18. Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma. J Exp Med. 2007;204:633-643. PMID: 17353367
  19. Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120:3884-3895. PMID: 25060588
  20. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-2263. PMID: 23335369
  21. Tilly H, Dreyling M; for ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):110-112. PMID: 19454426
  22. Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program. 2005;252-259. PMID: 16304389
  23. Moskowitz CH. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol. 2006;17(suppl 4):iv37-iv39. PMID: 16702184
  24. Mey UJ, Jha V, Strehl JW, et al. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. Ger Med Sci. 2007;5:Doc02. PMID: 19675710
  25. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol. 2012;2:188. PMID: 23248775
  26. Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:147-163. PMID: 21658615
  27. Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005:314-320. PMID: 16304397
  28. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164-1174. PMID: 15855278
  29. US National Institutes of Health. ClinicalTrials.gov website. http://www.clinicaltrials.gov. Accessed June 4, 2018.
  30. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: Food and Drug Administration; May 2007.
  31. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. PMID: 17242396